Suven gets patents from New Zealand, Eurasia

Drug firm Suven Life Sciences has received four product patents for its new chemical entities (NCEs), used in treating disorders like Alzheimer's disease, Parkinson and Schizophrenia. The company has received two patents each from New Zealand and Eurasia, which are valid until 2022 and 2025 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. The molecules in the CNS arena that are being developed for cognitive disorders have an estimated $30 billion market potential globally. Products of these inventions may be out licensed at various phases of clinical development like phase I or phase II.